Intermittent preventive treatment against malaria in infants in Gabon - A randomized, double-blind, placebo-controlled trial

Journal of Infectious Diseases

Volumn 196, Issue 11, 2007, Pages 1595-1602

  Grobusch, Martin P ^a,b,c   Lell, Bertrand ^a,b   Schwarz, Norbert G ^a   Gabor, Julian ^a   Dörnemann, Jenny ^a   Pötschke, Marc ^a   Oyakhirome, Sunny ^a   Kiessling, Georg C ^a   Necek, Magdalena ^a   Längin, Matthias U ^a   Klouwenberg, Peter Klein ^a   Klöpfer, Anna ^a   Naumann, Benjamin ^a   Altun, Handan ^a   Agnandji, Selidji T ^a   Goesch, Julia ^a   Decker, Marieluise ^a   Ospina Salazar, Carmen L ^a   Supan, Christian ^a   Kombila, Davy U ^a   Borchert, Lea ^a   Köster, Kai B ^a   Pongratz, Peter ^a   Adegnika, Akim A ^a   Von Glasenapp, Isabelle ^a   Issifou, Saadou ^a   Kremsner, Peter G ^a,b   more..

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARSUCAM; ARTESUNATE; FANSIDAR; PLACEBO; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; HEMOGLOBIN; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ANEMIA; APPETITE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GABON; GASTROINTESTINAL TOXICITY; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN TOXICITY; WEAKNESS; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; HEMATOCRIT; INCIDENCE; INFANT; KAPLAN MEIER METHOD; MALARIA FALCIPARUM; METABOLISM; METHODOLOGY; PARASITEMIA; PARASITOLOGY; PATIENT SELECTION; TREATMENT OUTCOME;

ANEMIA; ANTIMALARIALS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GABON; HEMATOCRIT; HEMOGLOBINS; HUMANS; INCIDENCE; INFANT; KAPLAN-MEIERS ESTIMATE; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PATIENT SELECTION; PYRIMETHAMINE; RESEARCH DESIGN; SULFADOXINE; TREATMENT OUTCOME;

EID: 38449102692     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522160     Document Type: Article

References (31)

1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004; 4:327-36.
2. Greenwood BM, Bojang K, Whitty CJM, Targett GAT. Malaria. Lancet 2005; 365:1487-98.
3. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycaemia and complications of pregnancy. Am J Trop Med Hyg 2001; 64(1-2 Suppl):57- 67.
4. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anemia control at time of routine vaccinations in Tanzanian infants: a randomized, placebo-controlled trial. Lancet 2001; 357:1471-7.
5. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine- pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 59:813-22.
6. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998; 92:141-50.
7. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine- pyrimethamine to prevent severe anemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353:632-6.
8. Rogerson SJ, Chaluluka E, Kanjala M, et al. Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-1999. Trans R Soc Trop Med Hyg 2000; 94:549-53.
9. World Health Organization (WHO). A strategic framework for malaria prevention and control during pregnancy in the African Region. Report AFR/MAL/04/01. Brazzaville: WHO Regional Office for Africa, 2004: 10-12. Available at: http://www.who.int. Last accessed March 2007.
10. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health 2005; 10:815-7.
11. Schellenberg D, Cisse B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitol 2006; 22:296-300.
12. Alloueche A, Bailey W, Barton S, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children. Lancet 2004; 363:1843-8.
13. Deloron P, Mayombo J, Le Cardinal A, et al. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans R Soc Trop Med Hyg 2000; 94:188-90.
14. Aubouy A, Jafari S, Huart V, et al. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine- pyrimethamine treatment efficacy. J Antimicrob Chemother 2003; 52:43-9.
15. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-91.
16. Planche T, Krishna S, Kombila M, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 2001; 65:599-602.
17. World Health Organization (WHO). Severe and complicated malaria, 3rd edition. Trans R Soc Trop Med Hyg 2000; 94(Suppl 1):1-90.
18. Schwarz NG, Oyakhirome S, Pötschke M, et al. 5-day non-observed artesunate monotherapy for treating uncomplicated malaria in young Gabonese children. Am J Trop Med Hyg 2005; 73:705-9.
19. Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365-72.
20. Lell B, May J, Schmitt-Ott RJ, Lehman LG, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis 1999; 28:794-9.
21. Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomized, placebo-controlled trial. Lancet 2005; 365:1481-3.
22. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in an area of high, seasonal transmission in Ghana. Brit Med J 2005; 331:727-33.
23. Macete E, Aide P, Aponte JJ, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambiquan infants: a randomized, placebo-controlled trial. J Infect Dis 2006; 194:276-85.
24. Klein Klouwenberg PM, Oyakhirome S, Schwarz NG, et al. Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. Acta Trop 2005; 95:81-5.
25. Massaga JJ, Kitua AY, Lemnge MM, et al. Effect of intermittent treatment with amodiaquine on anemia and malarial fevers in infants in Tanzania: a randomized placebo-controlled trial. Lancet 2003; 361:1853-60.
26. Bouchet C, Guillemin F, Briancon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996; 49:15-20.
27. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 2006; 80:582-96.
28. Danis M, Bricaire F. The new drug combinations: their place in the treatment of uncomplicated falciparum malaria. Fundam Clin Pharmacol 2003; 17:155-60.
29. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004; 364:1754-5.
30. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull WHO 1991; 69:297-304.
31. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25-61.